Trevena raises $24,000,000

Trevena, Inc., a drug discovery company focused on developing pharmaceutical products targeting G-protein coupled receptors (GPCRs), today announced the closing of a $24 million Series A financing.  GPCRs are proteins on the surface of cells that play a crucial role in receiving chemical signals from other cells and, in response, activating cellular responses. An estimated 40 percent of all existing drugs — including certain drugs used to treat allergies, ulcers, high blood pressure and migraine headaches — work by targeting GPCRs.